NuCana plc (NCNA)

3,8450 +0,0050 (+0,13%) In data: 12:30PM EDT. Mercato aperto.

NuCana plc

3 Lochside Way
Edinburgh EH12 9DT
United Kingdom
44 13 1357 1111
https://www.nucana.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 25

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Hugh Stephen Griffith	Founder, CEO & Executive Director	1,21M	N/D	1968
Mr. Donald Munoz	Chief Financial Officer	N/D	N/D	1969
Mr. David Harrison	Head of Translational Medicine	N/D	N/D	1960
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.	Chief Medical Officer	N/D	N/D	1958
Ms. Theresa Bruce	Senior Vice President of Clinical Operations	N/D	N/D	N/D
Ms. Elisabeth Oelmann	Senior Vice President of Medical & Clinical Development	N/D	N/D	N/D
Martin Quinn	Company Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di NuCana plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.